Literature DB >> 15050719

Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue.

Angela M Bodles1, Omar M A El-Agnaf, Brett Greer, David J S Guthrie, G Brent Irvine.   

Abstract

Alpha-synuclein has been linked to amyloidogenesis in Parkinson's disease and other neurodegenerative disorders. We have previously shown that a peptide comprising residues 68-78 of alpha-synuclein is the minimum fragment that, like alpha-synuclein itself, forms amyloid fibrils and exhibits toxicity towards cells in culture. Hughes et al. [J. Biol. Chem. 275 (2000) 25109] showed that an N-methylated derivative of Abeta(25-35) inhibited the formation of fibrils by Abeta(25-35) and reduced its toxicity. We have now extended this concept to an amyloidogenic alpha-synuclein-based peptide. Alpha-synuclein(68-78), N-methylated at G1y73, was compared to non-methylated peptide. Whereas alpha-synuclein(68-78) formed fibrils and was toxic to cells, the N-methylated analogue had neither of these properties. Moreover, an equimolar mixture of the non-methylated and methylated peptides formed very few fibrils and toxicity was markedly reduced.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050719     DOI: 10.1016/j.neulet.2003.12.077

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  21 in total

Review 1.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

Review 2.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 3.  Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases.

Authors:  G Brent Irvine; Omar M El-Agnaf; Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

4.  β-III Tubulin fragments inhibit α-synuclein accumulation in models of multiple system atrophy.

Authors:  Yasuyo Suzuki; Chenghua Jin; Tamaki Iwase; Ikuru Yazawa
Journal:  J Biol Chem       Date:  2014-07-15       Impact factor: 5.157

Review 5.  Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.

Authors:  Dena A M Amer; G Brent Irvine; Omar M A El-Agnaf
Journal:  Exp Brain Res       Date:  2006-05-30       Impact factor: 1.972

6.  Structure and topology of the non-amyloid-beta component fragment of human alpha-synuclein bound to micelles: implications for the aggregation process.

Authors:  Marco Bisaglia; Alessandra Trolio; Massimo Bellanda; Elisabetta Bergantino; Luigi Bubacco; Stefano Mammi
Journal:  Protein Sci       Date:  2006-06       Impact factor: 6.725

7.  Kinetic studies of inhibition of the amyloid beta (1-42) aggregation using a ferrocene-tagged β-sheet breaker peptide.

Authors:  Lin Zhang; Gargey Yagnik; Yong Peng; Jianxiu Wang; H Howard Xu; Yuanqiang Hao; You-Nian Liu; Feimeng Zhou
Journal:  Anal Biochem       Date:  2012-12-08       Impact factor: 3.365

8.  The influence of phospholipid membranes on bovine calcitonin secondary structure and amyloid formation.

Authors:  Steven S-S Wang; Theresa A Good; Dawn L Rymer
Journal:  Protein Sci       Date:  2005-05-09       Impact factor: 6.725

Review 9.  Targets for neuroprotection in Parkinson's disease.

Authors:  Talene A Yacoubian; David G Standaert
Journal:  Biochim Biophys Acta       Date:  2008-10-01

Review 10.  Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.

Authors:  H Akiko Popiel; Toshihide Takeuchi; James R Burke; Warren J Strittmatter; Tatsushi Toda; Keiji Wada; Yoshitaka Nagai
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.